A high dose of magnesium pidolate raises magnesium levels inside human brain organoids more than magnesium sulfate does, but this increase doesn't happen because the cells make more of the proteins that normally move magnesium in or out.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether magnesium pidolate consistently achieves higher intraorganoid magnesium levels than other magnesium salts across human brain organoid models under standardized conditions.
A systematic review and meta-analysis of all published human brain organoid studies comparing intraorganoid Mg2+ levels after exposure to MgPid, MgSO4, MgL-threonate, or other salts, pooling data from at least 10 studies using identical measurement protocols.
Whether magnesium pidolate causes higher intraorganoid Mg2+ than magnesium sulfate in human brain organoids under controlled conditions.
A double-blind, randomized trial using 50 organoids from independent iPSC lines, assigned to 5 mM MgPid, 5 mM MgSO4, or control, with intraorganoid Mg2+ measured via QuantiChrom assay at 24, 48, and 72 hours post-treatment, blinded to group.
Whether increasing magnesium concentration over time correlates with progressive accumulation of Mg2+ in organoids, and whether this differs between MgPid and MgSO4.
A longitudinal cohort study tracking 40 organoids exposed to 1, 3, or 5 mM MgPid or MgSO4 over 7 days, with daily Mg2+ measurements to assess accumulation kinetics and salt-specific differences.
Whether magnesium salt form at a single concentration is associated with intraorganoid Mg2+ levels across diverse organoid lines.
A cross-sectional analysis of 60 organoids from different iPSC lines exposed to 5 mM MgPid, MgSO4, or MgCl2 for 4 days, with intraorganoid Mg2+ measured at endpoint to assess salt-specific differences.
Whether organoids derived from individuals with mutations in magnesium transporters show altered Mg2+ accumulation in response to MgPid.
A case series of 5–10 organoid lines derived from individuals with known CNNM2 or TRPM6 mutations, exposed to 5 mM MgPid, to assess whether Mg2+ accumulation is impaired or enhanced compared to controls.